Global Dry Eye Disease Market Development Scenario and Regional Expansion Forecasted till 2025

Market Research Reports Search Engine (MRRSE) has announced the inclusion of a fresh study titled “Dry Eye Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025” to its massive database, which offers a crystal clear overview of market covering market dynamics such as factors, restraints, and opportunities present in the global market. It has been reported that numerous key players are investing in the development of new treatments for dry eye disease which is projected to drive the expansion of the global dry eye disease market.

Download Sample Copy in a PDF Format @ https://www.mrrse.com/sample/4343

To provide better and accurate results, the report majorly focuses on some of the prime regions including the Middle East and Africa (MEA), Europe, Asia Pacific, North America, and Latin America. All these are analyzed in terms of market revenue.

Market Overview and Forecast Evaluations

Dry eyes are a condition that is becoming progressively more well-known and suffered from around the world. This is a multifactorial disease which is considered by an insufficiency of tears in the eye. Presently, rising awareness among patients and surging healthcare expenditures have created an environment which is conducive to the market’s growth. As per the study key findings, the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Increasing at this pace, in terms of revenue the global dry eye disease market is projected to rise to US$ 7,780.0 Mn by 2025, which had a valuation of US$ 5,045.2 Mn in 2016.

The choice of treatment depends upon the type and severity of dry eye disease. In order to provide a comprehensive view, the global dry eye disease market has been segmented on the basis of product type, treatment and distribution channel. Major product type includes Artificial Tears, Punctal Plugs, Anti-inflammatory Drugs, Lifitegrast, Cyclosporine, Secretagogue and Corticosteroids. Of them, anti-inflammatory drugs segment is projected to lead the market in terms of revenue and continues to dominate the market till 2025, followed by artificial tears segment.

In terms of geography, North America arose as the largest market for dry eye disease globally on the back of the presence of a sophisticated healthcare infrastructure. Moving further, the introduction of new anti-inflammatory drugs such as Lifitegrast (Xiidra) and advancements in the existing cyclosporine eye drops is estimated to propel expansion of this segment.

Competitive Landscape

Moreover, key players are also mentioned in the report along with their market positioning, growth strategies and recent developments. Major companies are Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, Otsuka Pharmaceutical Co., Ltd., TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Johnson & Johnson, Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Mitotech S.A. and FCI S.A.S.

Browse Full Global Dry Eye Disease Market Report with TOC : https://www.mrrse.com/dry-eye-disease-market

About (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

Contact

State Tower
90, State Street Suite 700
Albany, NY – 12207 (United States)
Telephone: +1-518-730-0559
Email: sales@mrrse.com
Website: https://www.mrrse.com/

This release was published on openPR.